Skip to main content

Table 2 Changes in height SDS of children with X-linked hypophosphatemia followed-up until final height

From: Growth hormone treatment improves final height in children with X-linked hypophosphatemia

Time points of follow-up

Patients treated with rhGH (n = 34)

Patients non treated with rhGH (n = 29)

Age, years

Height SDS

Age, years

Height SDS

Mean ± SD

Mean ± SD

Mean ± SD

Mean ± SD

Birth

− 0.5 ± 1.9

0.5 ± 1.2

Diagnosis

3.5 ± 3.4

− 2.2 ± 1.2

2.6 ± 2.6

− 0.8 ± 1.6

Start of rhGH

9.8 ± 3.5

− 2.4 ± 0.9

9.8 ± 0.0

− 0.7 ± 0.9

After 2 years of rhGH

11.8 ± 3.4

− 1.4 ± 0.7

11.9 ± 0.0

− 0.9 ± 0.9

At the end of rhGH

14.2 ± 3.1

− 1.2 ± 0.9

14.2 ± 0.0

− 1.1 ± 1.1

Final height

18.3 ± 3.2

− 1.3 ± 0.9

16.9 ± 2.1

− 1.2 ± 1.1

165.5 ± 6.4 cm in boys 155.5 ± 6.3 cm in girls

165.4 ± 6.8 cm in boys 153.7 ± 7.8 cm in girls

Height gain at the end of rhGH

1.2 ± 0.7

Height gain at final height

1.2 ± 0.9

  1. rhGH: Recombinant human growth hormone; SDS: standard deviation score or Z-score